Results 171 to 180 of about 1,131,346 (296)

School uniforms, religious, symbols and the Human Rights Act 1998: the 'purity ring' case

open access: yes, 2008
The paper comments on the decision of the High Court in R (Playfoot) v Governing Body of Millais School (the ‘purity ring’ case), where the court was asked to rule on whether the school’s governing body’s decision not to allow Lydia Playfoot to wear a ...
Bacquet, S.
core  

Evaluating the influence of different anticoagulant blood collection tubes on the efficiency of circulating RNA extraction and Real-Time PCR quantification. [PDF]

open access: yesMol Biol Rep
Di Ruvo M   +8 more
europepmc   +1 more source

Translating whole‐genome doubling into precision medicine in cancer

open access: yesMolecular Oncology, EarlyView.
Whole‐genome doubling creates a WGD‐positive tumor state characterized by persistent chromosomal instability, karyotypic diversification, and cellular stress. These same biological pressures drive aggressive tumor evolution while exposing therapeutic vulnerabilities, providing a rationale for WGD‐informed precision medicine. Whole‐genome doubling (WGD)
Sejung Lee, Junghyeok Lim, Jinhyuk Bhin
wiley   +1 more source

Personal Papers (MS 80-0002)

open access: yes, 1963
Statement for items sold to Mrs. A. W.
Purity Ice Cream Company
core  

Improvement of precise large-fragment deletion with a versatile nuclease prime editor. [PDF]

open access: yesCell Discov
Li X   +12 more
europepmc   +1 more source

CEACAM1 participation in breast cancer progression

open access: yesMolecular Oncology, EarlyView.
In invasive breast cancer (BC), CEACAM1 shifts from an apical to a uniform membranous/cytoplasmic pattern, or is lost, as tumors dedifferentiate, inversely tracking the Ki‐67 proliferative index. In MCF‐7 cells, only CEACAM1‐4L suppresses proliferation, repressing cell cycle and growth factor genes.
Mykola Lyndin   +3 more
wiley   +1 more source

Pharmacological chromatin remodeling enhances response to estrogen therapy in ER+ breast cancer

open access: yesMolecular Oncology, EarlyView.
Estrogen therapy elicits clinical benefit in ~ 30% of patients with endocrine‐resistant estrogen receptor (ER)‐positive breast cancer. Based on findings that ER transcriptional activation underlies response to estrogen therapy, we tested the effects of epigenetic dysregulation via pharmacological inhibition of histone deacetylases (HDACi).
Anneka L. Johnson Thomas   +16 more
wiley   +1 more source

Home - About - Disclaimer - Privacy